The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Mucopolysaccharidosis I: Management and Treatment Guidelines
Abstract
OBJECTIVE. Disease management for mucopolysaccharidosis type I has been inconsistent because of disease rarity (∼1 case per 100000 live births), phenotypic heterogeneity, and limited therapeutic options. The availability of hematopoietic stem cell transplantation and the recent introduction of enzyme replacement therapy for mucopolysaccharidosis I necessitate the establishment of system-specific management guidelines for this condition. METHODS. Twelve international experts on mucopolysaccharidosis I met in January 2003 to draft management and treatment guidelines for mucopolysaccharidosis I. Initial guidelines were revised and updated in 2008, on the basis of additional clinical data and therapeutic advances. Recommendations are based on our extensive clinical experience and a review of the literature. RESULTS.All patients with mucopolysaccharidosis I should receive a comprehensive baseline evaluation, including neurologic, ophthalmologic, auditory, cardiac, respiratory, gastrointestinal, and musculoskeletal assessments, and should be monitored every 6 to 12 months with individualized specialty assessments, to monitor disease progression and effects of intervention. Patients are best treated by a multidisciplinary team. Treatments consist of palliative/supportive care, hematopoietic stem cell transplantation, and enzyme replacement therapy. The patient's age (>2 years or ≤2 years), predicted phenotype, and developmental quotient help define the risk/benefit profile for hematopoietic stem cell transplantation (higher risk but can preserve central nervous system function) versus enzyme replacement therapy (low risk but cannot cross the blood-brain barrier). CONCLUSION. We anticipate that provision of a standard of care for the treatment of patients with mucopolysaccharidosis I will optimize clinical outcomes and patients' quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,514
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Wilson, W., Taubert, K. A., Gewitz, M., Lockhart, P. B., Baddour, L. M., Levison, M., Bolger, A., Cabell, C. H., Takahashi, M., Baltimore, R. S., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.183095 · Cited by 2,814
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Human Gene Mutation Database (HGMD®): 2003 update: HGMD 2003 UPDATE
Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S. T., Abeysinghe, S., Krawczak, M., & Cooper, D. N. (2003) · Human Mutation · doi:10.1002/humu.10212 · Cited by 1,829
Enzyme-Replacement Therapy in Mucopolysaccharidosis I
Kakkis, E. D., Muenzer, J., Tiller, G. E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101183440304 · Cited by 667
Self-citationPastores, G. M. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00036-6 · Cited by 633
Wraith, J. E., Clarke, L. A., Beck, M., Kolodny, E. H., Pastores, G. M., Muenzer, J., Rapoport, D. M., Berger, K. I., Swiedler, S. J., Kakkis, E. D., et al. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.01.046 · Cited by 547
Self-citationHOBBS, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91046-1 · Cited by 488
Cited by
Overview of the mucopolysaccharidoses
Muenzer, J. (2011) · Rheumatology · doi:10.1093/rheumatology/ker394 · Cited by 486
Self-citationHematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome
Gentner, B., Tucci, F., Galimberti, S., Fumagalli, F., De Pellegrin, M., Silvani, P., Camesasca, C., Pontesilli, S., Darin, S., Ciotti, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106596 · Cited by 171
ZFN-mediated in vivo genome editing corrects murine hurler syndrome
Ou, L., DeKelver, R. C., Rohde, M., Tom, S., Radeke, R., St. Martin, S. J., Santiago, Y., Sproul, S., Przybilla, M. J., Koniar, B. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.018 · Cited by 84
Metadata
- Authors
- Muenzer, J., Wraith, J. E., Clarke, L. A., & and the International Consensus Panel on the Management and Treatment of Mucopolysaccharidosis, I.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2009-01-01
- Volume
- 123
- Issue
- 1
- Pages
- 19-29
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2043754477
- Cited by
- 460
- References
- 52
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mucopolysaccharidosis I: Management and Treatment Guidelines. https://app.cochat.ai/papers/10.1542/peds.2008-0416
- The paper
- Muenzer, J., Wraith, J. E., Clarke, L. A., & and the International Consensus Panel on the Management and Treatment of Mucopolysaccharidosis, I. (2009). Mucopolysaccharidosis I: Management and Treatment Guidelines. Pediatrics. https://doi.org/10.1542/peds.2008-0416
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.